US-based telemedicine consultation services provider Craft Telemedicine has launched a human-centred telemedicine platform, offering patients control over their healthcare choices.
The platform eliminates subscription models, allowing patients to pay per prescription and choose any pharmacy for their medications.
Unlike traditional telehealth services, it aims to provide transparency and freedom.
The platform was developed in collaboration with The Art of Medicine and ensures pharmaceutical-grade quality standards.
Stephen Stearman, an experienced healthcare entrepreneur, leads the initiative under the Craft Health Group.
Furthermore, Craft Telemedicine is expanding its network by partnering with compounding pharmacies across the US.
Clarity CEO and Co-Founder Arlee Riveland said: “Clarity is a form of care. I didn’t set out to found a healthcare company, but I did set out to build human-centred tools that solve real problems. And this one matters.
“We’re building a network of trusted compounding pharmacies that share our commitment to quality and patient care. We’re not just delivering prescriptions—we’re restoring agency to patients.”
Craft Telemedicine focuses on speciality compounded medications, starting with Low-Dose Naltrexone and Methylene Blue.
The treatments are often challenging to access through conventional healthcare channels.
Craft Telemedicine aims to become the preferred platform for pharmacies seeking to expand their patient base while maintaining their independence.
Currently, the company offers service plans in 25 states, with plans to cover all 50 states by 2026.
The Art of Medicine co-founder and pharmacist Jack Korbutov said: “When patients search for Methylene Blue online, they’re flooded with options that range from aquarium treatments to industrial dyes.
“Many people don’t realise that what they’re buying isn’t pharmaceutical-grade and heavy metal-free. This could actually be harmful.”
